ISSN
1916-694X

2010;
Volume 1 (Number 1): Pages 1-2

EDITORIAL

A new journal is out of the box

Alejandro
A. NAVA-OCAMPOa,b

aDepartment of Pharmacology & Toxicology,
Faculty of Medicine, University of Toronto, Toronto, Canada

bPharmaReasons, Toronto ON, Canada

Correspondence:
[email-masked]

In
a time of rapid changes, with well-respected publishers around the world
printing journals with high ranking citations, we are assisting in the creation
of the Journal of Clinical Pharmacology & Pharmacoepidemiology.

Only
a couple of years ago, together with a small but very enthusiastic group of
colleagues from at least three different countries from two different
continents, we made a decision to publish this journal based on an idea
conceived well before we had any experience writing protocols, analyzing data,
and drafting and peer-reviewing manuscripts.

I
was both extremely pleased and surprised when scientists from 15 different
countries joined to our venture as part of the Editorial Board.

From
this point, we moved forward step by step, firmly convinced to create a journal
publishing the entire spectrum of clinical and epidemiological studies related
to drug development, from phase I to IV, including, pharmacokinetic studies,
drug-drug interaction, dose-response, dose-finding, and dose-minimization
evaluations, pharmacoeconomic studies, systematic reviews, meta-analyses and
pharmacovigilance studies.

Case
reports are also considered for publication if there is a clear novel
contribution to the diagnosis or treatment of an adverse drug reaction or acute
poisoning. Analyses of philosophical, ethical or social aspects of drug
research in humans are also welcome.

The
delivery of the first issue of the journal was an enormous responsibility. The
‘cooking’ process was long, and in some cases tedious, but it never stopped.
All the manuscripts were reviewed by one member of the Editorial Board and by
at least one external reviewer, and in order to minimize any potential conflict
of interests, I was not involved in the editorial process of the papers coauthored
by myself.

In
this issue, the first of the journal, we were able to include one review paper
written by an international authority in the study of drug safety in pregnancy,
two original papers, and a case report. Adrienne EINARSON reviewed the various
methods of studying drug use in pregnancy and described their strengths and
weaknesses and supported each by examples from the literature to illustrate
each method [1]. In a retrospective cohort
study design, PARK et al. showed that uterine hyperactivity induced by
intravaginal administration of controlled-release dinoprostone may increase the
rate of cesarean sections without increasing the frequency of neonatal adverse
outcomes [2]. DESJARDINS et al.
demonstrated that the removal of rofecoxib from the Ontario and Québec markets
resulted in an immediate decrease followed by a slow increase in all NSAID
claims [3]. Finally, HONG et al.,
reporting a case of paternal exposure to irbesartan as part of a combination
therapy with other antihypertensive drugs and antidiabetics, suggested that
irbesartan does not alter sperm cells or increase the risk for fetal
malformations [4].

The
journal is published electronically in the English language only. However, the
abstracts are available in three different languages. Translation of the
abstracts to French and Spanish was made possible by colleagues who
spontaneously volunteered for this task.

This
issue was supported by submission fees for original papers and case reports and
by generous support from PharmaReasons, Toronto, Canada. However, the final
acceptance of the manuscripts was independent of the journal’s supporter. All
the manuscripts can be downloaded at no cost.

As
Editor, I express gratitude to my friends and colleagues who worked alongside
with me since the beginning of this project. I appreciate the effort of all the
members of the Editorial Board, the external reviewers, and the personnel
involved in the editing and publishing processes. Finally, the authors and the
readers of this journal deserve a note of gratitude for trusting us.

We
already have received enough material for the next issue, and we are extremely
committed to decrease the long timelines that it took to process the
manuscripts from their submission to their publication.

We
are improving every day, and your participation is always welcome.

Thank
you to all of you!

REFERENCES

[1]
Einarson A. Studying
the safety of drugs in pregnancy: and the gold standard is... J Clin Pharmacol
Pharmacoepidemiol 2010; 1: 3-8.

[2]
Park
H, Han JY, Ahn HK, Choi JS, Cho SI, Velázquez-Armenta EY, et al. Unintentional
uterine hyperactivity and perinatal outcomes following labor induction with
intravaginal administration of sustained-release dinoprostone insert. J Clin Pharmacol
Pharmacoepidemiol 2010; 1: 9-14.

[3]
Desjardins O, Manley J, Nanwa N, Goh YI, Smith R,
Einarson TR. Trends in prescription claims following the withdrawal of rofecoxib
from the Canadian market. J
Clin Pharmacol Pharmacoepidemiol 2010; 1: 15-23.

[4]      Hong SC, Han JY, Choi SJ, Ahn HK, Velázquez-Armenta
EY, et al. Paternal exposure
to irbesartan coadministered with multiple antihypertensive and antidiabetic
drugs: a case report of a baby born healthy. J
Clin Pharmacol Pharmacoepidemiol 2010; 1: 24-26.

www.Premiumreasons.com/JCPPE/JCPPE.html

© PremiumReasons